BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36640208)

  • 1. Peri-osteosarcoma adipose computed tomography attenuation and volume for predicting chemotherapy response in pediatric patients.
    Fu D
    Clin Transl Oncol; 2023 Jun; 25(6):1710-1718. PubMed ID: 36640208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs.
    Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A
    J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
    Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
    Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
    Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate pharmacokinetics and prognosis in osteosarcoma.
    Graf N; Winkler K; Betlemovic M; Fuchs N; Bode U
    J Clin Oncol; 1994 Jul; 12(7):1443-51. PubMed ID: 8021736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate for high-grade osteosarcoma in children and young adults.
    van Dalen EC; van As JW; de Camargo B
    Cochrane Database Syst Rev; 2011 May; 2011(5):CD006325. PubMed ID: 21563152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate for high-grade osteosarcoma in children and young adults.
    van Dalen EC; de Camargo B
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006325. PubMed ID: 19160278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen.
    Ferrari S; Sassoli V; Orlandi M; Strazzari S; Puggioli C; Battistini A; Bacci G
    J Chemother; 1993 Apr; 5(2):135-41. PubMed ID: 8515297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
    Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
    Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can pretreatment
    Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
    Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
    Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
    Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
    Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
    Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
    Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.